Hyperplasia News and Research

RSS

Study suggests less than 10% of UK adults with CAH receive specialist endocrine care

A new study suggests that less than 10% of the estimated 3,591 adults in the UK with the genetic condition congenital adrenal hyperplasia (CAH) receive specialist endocrine care, and that there is no standard treatment for these patients.

26 Nov 2010

PROTOX closes first tranche of investment by Warburg Pincus

Protox Therapeutics Inc., a leader in the development of receptor targeted therapeutic fusion proteins, today announced it has closed the first tranche of the investment by Warburg Pincus. The investment was approved by 100% of the votes cast by shareholders at the recent special shareholders meeting.

20 Nov 2010

Can Pfizer rescue hormonal replacement therapy?

In a market still plagued with safety concerns, Pfizer has an opportunity to restore market growth for hormonal replacement therapy (HRT) with its new combination product, Aprela. To do this it must rebuild public and general practitioner confidence in the therapy area, says independent market analyst, Datamonitor.

16 Nov 2010

Protox decreases third quarter net and comprehensive loss to $1.6 million

Protox Therapeutics Inc., a leader in the development of receptor targeted therapeutic fusion proteins, today released financial results for the third quarter, ended September 30, 2010.

15 Nov 2010

Nymox awarded federal grant for NX-1207 Phase III BPH clinical trial program

Nymox Pharmaceutical Corporation announced today that it has been awarded a grant of $244,479.25 from the U.S Government under the Qualifying Therapeutic Discovery Project for its ongoing Phase III clinical trial program for NX-1207 for the treatment of benign prostatic hyperplasia (BPH). The grant was the maximum allowable for an individual development program.

4 Nov 2010

Nymox updates NX-1207 Phase 3 pivotal trials for benign prostatic hyperplasia

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 pivotal trials for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH).

28 Oct 2010

Medicare reimbursement changes increase demand for intermittent catheters

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, reimbursement changes have caused the demand for intermittent catheters to increase significantly. In April 2008, Medicare changed reimbursement to cover up to 200 catheters per month, instead of the previous 4 that it covered.

26 Oct 2010

Scorpion’s toxins can reduce heart bypass failures: Research

A toxin found in the venom of the Central American bark scorpion (Centruroides margaritatus) could hold the key to reducing heart bypass failures, according to research from the University of Leeds.

22 Oct 2010

Research suggests lowering cholesterol can reduce benign prostatic hyperplasia

A cholesterol-lowering drug reduced the enlarged prostates of hamsters to the same extent as a drug commonly used to treat benign prostatic hyperplasia (BPH), report researchers at Children's Hospital Boston and their colleagues in the October issue of the Journal of Urology. Together, the drugs worked even better.

22 Oct 2010

Focused Ultrasound Surgery Foundation hosts conference to discuss advancements in therapeutic medicine

The Focused Ultrasound Surgery Foundation is hosting the 2nd International Symposium on MR-guided Focused Ultrasound in Chantilly, Virginia from October 17-20. Leading researchers and clinicians from around the world will gather at the three-day scientific conference to present and discuss the latest advancements in one of the most revolutionary and promising areas of therapeutic medicine.

6 Oct 2010

Public hospitals in two Australian states acquire GreenLight HPS laser consoles for BPH treatment

American Medical Systems, a leading provider of world-class devices and therapies for male and female pelvic health, today announced that eight GreenLight HPS® laser consoles have been acquired for public hospitals in the Australian states of Victoria and Queensland. The laser technology will treat patients with Benign Prostatic Hyperplasia (BPH), a non cancerous enlargement of the prostate experienced by 50 percent of men over 60.

4 Oct 2010

Warburg Pincus to invest CDN $35 million in Protox

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins for the treatment of diseases of the prostate and cancer, and Warburg Pincus, a leading global private equity firm, today jointly announced that they have entered into an Investment Agreement.

30 Sep 2010

Intrauterine devices for treatment of endometrial cancer

Intrauterine devices, originally developed as contraceptives, can also be used to treat and cure cancer of the endometrium according to new research published online in the cancer journal, Annals of Oncology today (Wednesday 29 September). The finding opens the way for young women with the disease, which affects the lining of the womb, to be treated without the need for a hysterectomy, thus preserving their fertility until they have had all the children they want.

29 Sep 2010

Clinical trial results of Genous Bio-engineered R stent, EPC capture technology presented at TCT 2010

OrbusNeich today announced that clinical trial results highlighting the company's Genous Bio-engineered R stent and its endothelial progenitor cell capture technology across challenging patient subsets were presented during a symposium titled "EPC Capture Technology: from Genous to Combo" at Transcatheter Cardiovascular Therapeutics 2010 in Washington.

27 Sep 2010

OrbusNeich completes enrollment in Combo Bio-engineered Sirolimus Eluting Stent clinical trial

OrbusNeich today announced at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 in Washington the completion of patient enrollment in the randomized clinical trial of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) with 183 patients included at sites in Asia, Australia, Europe and South America.

24 Sep 2010

Lutonix presents data on Moxy Drug Coated Balloon Catheter at TCT meeting

Lutonix, Inc., headquartered in Minneapolis, MN, today announced six-month data from three separate drug coated balloon studies presented at the TransCatheter Therapeutics (TCT) meeting this week demonstrated the ability of the Moxy Drug Coated Balloon Catheter to inhibit restenosis in both peripheral and coronary arteries.

24 Sep 2010

More men than women discontinue medications due to side effects

Men are more likely than women to discontinue a medication due to side effects. More and more men are diagnosed with age-related issues like enlarged prostate and men are being prescribed medications that have side effects. These side effects often cause men to say "NO." In the U.S. and Canada, Prostate prescriptions dominate the treatment of enlarged prostate.

10 Sep 2010

Endocrine Society releases new clinical practice guideline on congenital adrenal hyperplasia

Today, The Endocrine Society released a new clinical practice guideline on the diagnosis and treatment of congenital adrenal hyperplasia (CAH). The guideline features a series of evidence-based clinical recommendations developed by an expert task force.

7 Sep 2010

Urologix 2010 fourth quarter net loss decreases 28.9% to $0.04 per share

Urologix, a medical device company that develops, manufactures and markets minimally invasive Cooled ThermoTherapy™ technology to urologists to provide a durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), today reported financial results for its fourth quarter ended June 30, 2010 and for fiscal year 2010.

25 Aug 2010

EDAP's gross profit reduces 5.1% in 2010 second quarter

EDAP TMS SA, the global leader in therapeutic ultrasound, announced today financial results for the second quarter ended June 30, 2010. The Company outlines strategic initiatives to counter the continuing weak global economic climate.

24 Aug 2010